Cartesian Therapeutics, Inc. (RNAC) research
Cartesian Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $7.36
- As of
Cartesian Therapeutics, Inc. (RNAC): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-29.
As of . Source: SEC EDGAR filings for RNAC. Method and limitations.
Share the RNAC intelligence card
See the full RNAC dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RNAC on one page. Preview it with sample data, then open it live with a free account.
Preview the RNAC dossierActive signals for RNAC
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 70% of RNAC (2026Q2)
- mediumNEW_POSITION
D. E. Shaw & Co., Inc. new position in RNAC
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +77% to RNAC (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 151.9%, EPS $0.46 vs $-0.8859 estimate
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +64% to RNAC (2026Q1)
FREE, NO ACCOUNT
Every signal on RNAC, as it fires
You are seeing 5 of 10 signals recorded on RNAC since 2026-05-17.
The five above landed across 3 days. The other 5 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RNAC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 816212302 · 2026Q2 | $3.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 816212302 · 2026Q2 | $3.1M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 816212302 · 2026Q2 | $455K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 816212302 · 2026Q2 | $299K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 816212302 · 2026Q2 | $212K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RNAC
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
RNAC against its peers
RNAC's operating margin of -35851.2% ranks in the 8th percentile of 18 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | RNAC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 400000 USD | 27.5M USD | 18 | 19 |
| Gross margin | n/a | 58.3% | n/a | 5 |
| Operating margin | -35851.3% | -100.3% | 8 | 18 |
| Net margin | -32575.5% | -98.2% | 13 | 19 |
| Return on equity | n/a | -47.0% | n/a | 25 |
Peers (25): KROS, NAGE, CGEN, PLX, MGNX, ANTX, LYEL, PRQR, SION, LCTX, WHWK, SLGL, TRDA, ZNTL, IVVD, XGN, BCYC, ELDN, ALEC, NAUT, CUE, PALI, CAMP, IFRX, ANIK. Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (RNAC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more RNAC signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to RNACand get the insider, 13F, options, and confluence read in one view.